Novo Nordisk today announced that Health Canada has approved Levemir® FlexTouch®, a disposable prefilled insulin pen containing Levemir® (insulin detemir). Levemir® FlexTouch® has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes).
The approval was also announced at the 2013 Vascular Conference in Montreal, Quebec.
Levemir® FlexTouch® features a push-button that does not extend at any set dose and a unique spring-loaded mechanism, in which the injection is driven by a torque spring rather than the user's thumb pressure.1 The torque spring is loaded as the dose is set and the spring energy is activated by depressing the push-button. As a result, the injection force of FlexTouch® is significantly lower than other widely used prefilled pens.2 In 2012, Novo Nordisk announced the Health Canada approval of NovoRapid® FlexTouch®, which provided Canadians living with diabetes with the first preﬁlled insulin pen without a push-button extension for NovoRapid® (insulin aspart).3